Ovid Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Proactive news headlines: Eden Research, Primary Health Properties, Silence Therapeutics, IronRidge Resources.
A glance at some of the day s highlights from the Proactive Investors newswire
Eden Research PLC (LON:EDEN) said it has signed what it called a ‘milestone agreement’ with Corteva Agrisciences for its seed treatment application.
Primary Health Properties PLC (LON:PHP) said its rental collection has remained robust so far in 2021 as the healthcare facilities firm updated investors of its performance for the first quarter, while rental income from its existing portfolio continued to grow.
Great Western Mining Corporation PLC (LON:GWMO) said an initial six-hole drilling programme at the Trafalgar Hill prospect, part of the Olympic Gold project, has been completed “significantly ahead of schedule and under budget”.
(1)
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18 at 8:00 a.m. ET.
The live webcast of the presentation will be available on the Investors page of the Company s website. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merusis a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half
VITAL study 9-month results expected to be presented at a medical conference in 2021
Prasinezumab
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference
PRX004
PRX005
IND expected by 3Q 2021
$80 million potential payment from Bristol Myers Squibb upon exercising their US license option in 2021
PRX012, a potential treatment for Alzheimer’s disease, is a high affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ
IND expected by 1Q 2022
Upcoming Investor Conferences
Members of the senior management team will present and participate in investor meetings at the following upcoming investor conferences:
BofA Securities 2021 Virtual Health Care Conference, May 13, 2021, at 8:45 AM ET